The outsourcing of biologics development and manufacturing services across the product lifecycle would be driven by the expansion in biopharmaceutical sales and pipeline as well as the complexity of molecules.
The global biologics CDMO market is driven by the growing biopharmaceutical end market, rapidly expanding pipelines of cell & gene therapies & new vaccines, and significant VC funding.
